Expert InterviewWVE
Examining novel candidates for alpha-1 antitrypsin deficiency, including Beam Therapeutics’ BEAM-302 and Wave Life Sciences’ WVE-006
Expert Profile
- Pulmonologist at Blessing Heath Hannibal Clinic
- Manages over 400 patients at an Alpha-1 certified center and research center
- Primary research interest in AATD and developing therapies
Interview Goal
On this call, we will discuss emerging clinical data in alpha-1 antitrypsin deficiency (AATD), focusing on two novel disease-modifying approaches: Beam Therapeutics’ BEAM-302 (an in vivo base editing therapy) and Wave Life Sciences’ WVE-006 (a GalNAc-conjugated A-to-I RNA editing oligonucleotide). We will explore how clinicians interpret early biomarker efficacy signals (total AAT restoration, corrected M-AAT production, mutant Z-AAT reduction), durability expectations, safety and monitoring considerations, and how these modalities may be positioned relative to current standards of care (e.g., AAT augmentation therapy, transplant, and emerging liver-directed strategies). The call will also cover future adoption drivers, patient selection, and key evidence needed to support broader clinical use.